city New Delhi India covid-19 vaccine DNA city New Delhi India

Zydus Cadila to seek DCGI nod for 2-dose regimen of its approved 3-dose Covid-19 vaccine

Reading now: 227

New Delhi: Considering the burden on healthcare and the expense of buying three doses, Zydus Cadila is planning to seek approval for the two-dose regimen of its needle-free COVID-19 vaccine, ZyCoV-D, days after the vaccine was approved by India's drugs regulator for emergency use in India on August 20.

The trials for the two-dose regimen are underway. 2mg of the vaccine has been prescribed in each dose of the present-day three-dose vaccine i.e.

total of 6 mg. The company is now evaluating a 2 dose regime with 3mg in each dose. The vaccine is said to be pathbreaking as it is for the first time that a technologically advanced vaccine has been successfully developed on the Plasmid DNA platform for human use.

The website is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News